Skip to main content

Table 3 Multivariable analyses for the main study outcomes (immunovirological success and switch of treatment)

From: Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease

 

Logistic regression model Outcome: immunovirological success

Cox regression model Outcome: switch from first-line therapy

 

Adjusted odds ratio with 95%CI

p value

Adjusted hazard ratio with 95%CI

p value

Age (years)

    

   ≥ 50

2.03 (0.66-6.23)

0.214

1.83 (1.02-3.31)

0.044

   < 50

reference category

 

reference category

 

Transmission

    

   Heterosexual

reference category

 

reference category

 

   men who have sex with men

1.54 (0.52-4.56)

0.433

0.87 (0.47-1.60)

0.653

   IVDU/infected blood

0.72 (0.09-5.38)

0.746

0.60 (0.14-2.66)

0.503

HIV clinical stage

    

   AIDS

reference category

 

reference category

 

   non-AIDS

0.70 (0.26-1.85)

0.475

1.13 (0.86-1.50)

0.382

Baseline CD4+ (T cells/μL)

    

   < 100/μL

reference category

 

reference category

 

   ≥ 100/μL

2.93 (1.16-7.39)

0.023

1.00 (0.75-1.33)

0.997

Baseline HIV-RNA (copies/mL, log 10 )

    

   ≥ 5 log10/mL

reference category

 

reference category

 

   < 5 log10/mL

1.73 (0.56-5.38)

0.344

0.92 (0.65-1.29)

0.628

First-line therapy

    

   NNRTIs

reference category

 

reference category

 

   Unboosted PIs *

1.25 (0.25-6.25)

0.788

3.88 (1.40-10.7)

0.009

   Boosted PIs **

0.78 (0.25-2.41)

0.663

4.21 (1.70-10.4)

0.002

  1. * Unboosted PIs: 16 (indinavir: 7, nelfinavir: 8, saquinavir: 1);
  2. ** Boosted PIs: 62 (indinavir 2, lopinavir 60)